Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nebivolol Approval Could Come In Mid-2007, Forest Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.

You may also be interested in...



Forest Will Delay Nebivolol NDA For CHF Pending FDA Review Of Hypertension Data

Company is currently wrapping up pharmacokinetic studies needed to respond to an “approvable” letter for hypertension NDA.

Forest Will Delay Nebivolol NDA For CHF Pending FDA Review Of Hypertension Data

Company is currently wrapping up pharmacokinetic studies needed to respond to an “approvable” letter for hypertension NDA.

Forest Labs Aims To Launch Once-Daily Namenda Ahead Of Generics

Alzheimer's line-extension is in Phase III, and first ANDA with paragraph IV certification for current twice-daily formula could be filed next fall.

Related Content

Topics

UsernamePublicRestriction

Register

PS064063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel